Chromosomal assessment to differentiate histiocytic malignancy from lymphoma in dogs

1. A method for treating a dog with lymphoma, the method comprising:

(a) measuring copy numbers of CFA 2, CFA 16, and CFA 31 in a biological sample from a dog suspected of having lymphoma or a histiocytic malignancy, wherein:

(i) the biological sample comprises neoplastic cells; and

(ii) the copy numbers of CFA 2, CFA 16, and CFA 31 are measured by aberrations at CFA chr2:31,017,808-31,586,959, CFA chr16:31,674,246-32,429,051, and CFA chr31:33,346,317-33,709,291 from CamFam2, respectively;

(b) detecting a normal or elevated copy number at CFA 2, CFA 16, and CFA 31 compared to a normal control in the biological sample;

(c) diagnosing the dog with lymphoma; and

(d) treating the dog with standard of care (SOC) chemotherapy using either single agent or multiagent protocols.

2. The method of claim 1 , wherein the copy numbers are measured by fluorescence in situ hybridization (FISH).

3. The method of claim 1 , wherein the copy numbers are measured by polymerase chain reaction (PCR).

4. The method of claim 1 , wherein the copy numbers are measured by comparative genomic hybridization (CGH).

5. The method of claim 1 , wherein the copy numbers are measured by next generation sequencing.

6. The method of claim 1 , wherein the biological sample is a tissue sample.

7. The method of claim 1 , wherein the sample is a fresh-frozen sample.

8. The method of claim 1 , wherein the sample is a fresh sample.

9. The method of claim 1 , wherein the sample is a formalin-fixed, paraffin-embedded sample.

10. The method of claim 1 , wherein the copy numbers at CFA 2, CFA 16, and CFA 31 are measured with probes of about 15 to about 1×10 6 nucleotides in length.

11. The method of claim 10 , wherein the copy numbers are measured with probes of about 5,000 to about 800,000 nucleotides in length.

12. The method of claim 10 , wherein the copy numbers are measured with probes of about 100,000 to about 400,000 nucleotides in length.

13. A method for selecting and treating a dog suspected of having a canine lymphoma, the method comprising:

(a) providing a dog suspected of having a lymphoma or a histiocytic malignancy;

(b) measuring copy numbers of CFA 2, CFA 16, and CFA 31 in a biological sample from the dog, wherein:

(i) the biological sample comprises cells obtained directly from a suspected neoplastic mass; and

(ii) the copy numbers of CFA 2, CFA 16, and CFA 31 are measured by aberrations at CFA chr2:31,017,808-31,586,959, CFA chr16:31,674,246-32,429,051, and CFA chr31:33,346,317-33,709,291 from CamFam2, respectively;

(b) detecting normal or elevated copy number at CFA 2, CFA 16, and CFA 31 compared to a normal control in the biological sample;

(c) diagnosing the dog with lymphoma; and

(d) treating the dog with standard of care (SOC) chemotherapy using either single agent or multiagent protocols.

14. The method of claim 13 , wherein the copy numbers at CFA 2, CFA 16, and CFA 31 are measured with probes of about 15 to about 1×10 6 nucleotides in length.

15. The method of claim 14 , wherein the copy numbers are measured with probes of about 5,000 to about 800,000 nucleotides in length.

16. The method of claim 14 , wherein the copy numbers are measured with probes of about 100,000 to about 400,000 nucleotides in length.